Form 4: Agios Pharmaceuticals Director Cynthia Smith Reports New Equity Grants and RSU Vesting

Agios Pharmaceuticals, Inc. Director Cynthia Smith reported the vesting of previously granted restricted stock units and the acquisition of new equity awards, including restricted stock units and stock options.

Summary

• On June 18, 2025, Cynthia Smith, a Director of Agios Pharmaceuticals, Inc. (AGIO), was granted 2,816 Restricted Stock Units (RSUs) and 15,768 stock options.
• The newly granted RSUs and stock options are scheduled to vest in full on June 18, 2026.
• The stock options have an exercise price of $35.5 per share and an expiration date of June 18, 2035.
• On June 20, 2025, 2,120 Restricted Stock Units (RSUs) that were granted on June 20, 2024, vested and converted into 2,120 shares of common stock.
• Following these transactions, Cynthia Smith beneficially owns 10,112 shares of common stock directly, in addition to the newly granted 2,816 RSUs and 15,768 stock options.

Sentiment

Score: 7

Explanation: The sentiment is positive as the director received new equity grants and had existing RSUs vest, indicating continued alignment with shareholder interests and a strengthening of her stake in the company.

Positives

• Cynthia Smith received new grants of 2,816 Restricted Stock Units (RSUs) and 15,768 stock options, increasing her potential equity stake in the company.
• Previously granted 2,120 Restricted Stock Units vested and converted into common stock, demonstrating the realization of equity compensation.

Future Outlook

The document indicates future vesting events for the newly granted Restricted Stock Units and stock options, with full vesting expected on June 18, 2026. The stock options have an expiration date of June 18, 2035.

Industry Context

This Form 4 filing reflects routine equity compensation for a director in the biotechnology and pharmaceutical industry, a common practice to align management incentives with shareholder interests.

Stakeholder Impact

• Shareholders: The equity grants to a director align her interests with those of shareholders, potentially encouraging long-term value creation.
• Employees: While not directly impacting employees, such compensation practices are part of a broader corporate governance framework that can influence overall company culture and performance.

Next Steps

• Vesting of 2,816 Restricted Stock Units on June 18, 2026.
• Vesting of 15,768 stock options on June 18, 2026.
• Potential exercise of 15,768 stock options prior to their expiration on June 18, 2035.

Key Dates

Keywords

Agios Pharmaceuticals, AGIO, Cynthia Smith, SEC Form 4, Insider Transaction, Restricted Stock Units, Stock Options, Equity Compensation, Director Compensation, Biotechnology, Pharmaceuticals